The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 32 | — | 20.1x | Below average | |
Growth | 81 | 289.9% | 5.6% | Above average | |
Quality | 65 | 207.9% | 7.6% | Near average | |
Safety | 22 | 0.1x | 0.4x | Below average | |
Capital Return | 15 | — | 2.19% | Below average | |
Momentum | 20 | — | — | Below average | |
Sentiment | 27 | — | — | Below average |
Humacyte, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Humacyte, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
Humacyte stock has witnessed a notable positive shift in analyst estimates, with the average price target jumping by 86% to rise from $3 to $5.58. This increase is primarily attributed to a new analyst entering coverage with high estimates, bringing the number of active analysts to three, while maintaining 'Buy' ratings from major institutions such as TD Cowen and BTIG, reflecting growing optimism despite continued expected operating losses in earnings per share (EPS).
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.